New Strategies in Rheumatoid Arthritis Treatment: Treat-to-Target, How Much Do You Know?

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized primarily by erosive arthritis, with a global prevalence of approximately 0.5%-1%, and over 5 million patients in China. For a long time, RA treatment has aimed at reducing pain and controlling inflammation, but many patients still face joint destruction, functional loss, and decreased quality of life. In recent years, the "Treat-to-Target" (T2T) strategy has been widely recommended by the international rheumatology community, becoming a new benchmark in RA management. So, what exactly does Treat-to-Target mean? How does it change the treatment pathway for patients? This article provides an in-depth interpretation for you.

Core Principles of Treat-to-Target: Clear Goals, Dynamic Adjustment

Treat-to-Target is not a specific drug but a treatment philosophy. Its core concept is to achieve clinical remission or low disease activity as soon as possible by setting clear treatment goals collaboratively with the patient and regularly assessing and adjusting the plan. In 2010, the international T2T task force published the first recommendations for RA management, emphasizing:

Goals must be quantifiable: Composite disease activity indices are typically used, such as DAS28 (28-joint Disease Activity Score), CDAI (Clinical Disease Activity Index), or SDAI (Simplified Disease Activity Index). Remission is defined as DAS28 < 2.6, and low disease activity as DAS28 ≤ 3.2.

Regular monitoring: Assess monthly or every 1-3 months until the goal is achieved; thereafter, monitor every 3-6 months.

Treatment adjustment: If there is no improvement within 3 months (DAS28 decrease > 1.2 or ≥ 0.6), or the goal is not met within 6 months, the treatment plan should be adjusted, including escalating medication, combination therapy, or switching mechanisms of action.

This strategy abandons the passive "trial and error" approach of the past, pursuing measurable outcomes instead, and significantly improves remission rates. For example, a Dutch study showed that patients managed with the T2T strategy achieved clinical remission rates of 50%-60% within one year, compared to only 20%-30% with traditional treatment.

How to Set Individualized Goals? From Remission to Patient-Reported Outcomes

The goals of Treat-to-Target are not one-size-fits-all. For patients with short disease duration and favorable prognostic factors, pursuing clinical remission (no joint swelling, tenderness, and normal inflammatory markers) is a reasonable goal. However, for patients with long disease duration, existing joint damage, or comorbidities, low disease activity may be a more realistic target. Additionally, T2T emphasizes "patient-reported outcomes" (PROs), including pain scores, fatigue levels, physical function (e.g., HAQ-DI), and mental health, which should be incorporated into goal setting and efficacy evaluation.

Patients are core members of the treatment team. Physicians should communicate fully with patients, explaining the pros and cons of Treat-to-Target, and jointly develop individualized goals. For example, a 45-year-old female patient who wishes to maintain her ability to work would require goals that not only relieve joint symptoms but also preserve grip strength and exercise endurance. Therefore, at each follow-up visit, the physician should inquire about the patient's subjective feelings and adjust the plan based on objective indicators.

Pathways to Achieving Treat-to-Target: Medication Selection and Stepped Strategy

Treat-to-Target does not specify a particular class of drugs but emphasizes selecting the most appropriate treatment based on disease activity. Currently, commonly used medications include:

Conventional synthetic DMARDs (csDMARDs): Methotrexate is the cornerstone, typically starting at 10-15 mg/week, gradually increasing to 20-25 mg/week, with folic acid supplementation. If monotherapy fails to achieve the goal within 3 months, combination with other csDMARDs (e.g., sulfasalazine, hydroxychloroquine) or biologics should be considered.

Biologic DMARDs (bDMARDs): Such as TNF inhibitors (etanercept, adalimumab, etc.), IL-6 receptor antagonists (tocilizumab), CTLA4-Ig (abatacept), etc. If csDMARDs fail, bDMARDs can be initiated, often combined with methotrexate for better efficacy.

Targeted synthetic DMARDs (tsDMARDs): Such as JAK inhibitors (tofacitinib, baricitinib), which are convenient orally and have rapid onset.

For example, a patient with DAS28 = 5.8 starts on methotrexate with monthly monitoring. If DAS28 drops to 4.5 after 3 months (improvement > 1.2), the current plan is continued; if no improvement, a TNF inhibitor is added. If the goal is still not met after 6 months, adherence, drug levels, or switching to a different mechanism should be evaluated.

It is important to note that Treat-to-Target is not "the stronger, the better"; safety must also be weighed. Regular monitoring of liver and kidney function, blood counts, and infection risk is essential, especially when using biologics or JAK inhibitors.

Patient Self-Management: The Other Half of Treat-to-Target

The success of Treat-to-Target relies heavily on active patient participation. Studies show that poor adherence is a major cause of treatment failure. Patients should:

Take medications on time: Use pill organizers or phone reminders, and do not stop or reduce doses arbitrarily.

Record symptoms: Keep a daily log of joint pain, morning stiffness duration, and number of swollen joints to provide accurate information during follow-up visits.

Regular check-ups: Even if feeling well, attend scheduled blood tests and imaging to assess subclinical inflammation.

Lifestyle interventions: Engage in moderate exercise (e.g., swimming, walking), quit smoking, and maintain a healthy weight, all of which help reduce inflammation.

Additionally, patients can use Meijiakang's remote follow-up services to stay in communication with physicians and promptly report changes in their condition. For questions about international treatment plans, consult our expert team for personalized advice.

Recommendations for International Patients

For RA patients planning to come to China or currently receiving treatment in China, Treat-to-Target is equally applicable. Recommendations include:

Clarify goals during visits: Discuss your expectations with the physician and understand the meaning of indicators like DAS28.

Bring previous medical records: Including medication history, imaging results, and laboratory tests, to help physicians quickly formulate a strategy.

Utilize telemedicine: International patients can use online follow-up consultations to reduce travel burden.

Check medication accessibility: Some biologics are covered by medical insurance in China, but specific policies should be confirmed.

Be patient: Achieving the target typically takes 3-6 months; do not abandon treatment due to short-term lack of results.

Treat-to-Target offers RA patients greater possibilities for remission, but it requires joint efforts from both physicians and patients. If you want to know specific treatment costs, use the cost estimation tool for advance planning.

Let us work together toward a future free of pain and disability.